Barclays lowered the firm’s price target on Bristol Myers to $41 from $43 and keeps an Equal Weight rating on the shares as part of a Q2 earnings preview for the U.S. biopharmaceutical space. The analyst believes Pfizer (PFE), Eli Lilly (LLY) and Merck (MRK) “are set up for compelling updates,” while Travere Therapeutics’ (TVTX) momentum should continue into the FDA action date.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of July 1, 2024
- 2seventy Bio announces sale of Hemophilia A candidate for up to $40M
- Bristol Myers Squibb call volume above normal and directionally bullish
- Bristol Myers announces FDA accelerated approval of Krazati for CRC
- FDA approves Mirati’s Krazati sNDA for colorectal cancer